Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials)

By sjmartinez • June 27, 2023

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F; ENHANCE investigators. Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials). Am J Respir Crit Care Med. 2023 Jun 26. doi: 10.1164/rccm.202306-0944OC. Epub ahead of print. PMID: 37364283.

Tags: COPD, ensifentrine, nebulized, PDE3 and PDE4 inhibitor, Publications, Pulmonary, Critical Care & Sleep Medicine

Predicting Oral HIV Pre-Exposure Prophylaxis Efficacy in Cisgender Women Across Pregnancy and Postpartum

Yu Y, Brooks KM, Doncel GF, Best BM, Marzinke MA, Mirochnick M, Anderson PL, Myer L, Celum C, Heffron R, Coleman J, Davey DLJ, Zhang[...]

Association between Alzheimer’s disease-related genes and neurodegenerative blood-based biomarkers in Indian adults

Abu-Amara H, Zhao W, Li Z, Leung YY, Schellenberg GD, Wang LS, Crimmins EM, Thyagarajan B, Anwar M, Hu P, Dey S, Dey AB, Zhou[...]

Metastatic Melanoma Presenting As Small Bowel Obstruction

Ruci A, Chan SM, Kan CK, Fagel C, Maque J. Metastatic Melanoma Presenting As Small Bowel Obstruction. Cureus. 2026 Aug 2;18(8):e113827. doi: 10.7759/cureus.113827. PMID: 42688324;[...]